Reports Q2 revenue $141.148M, consensus $146.27M. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, “We’re incredibly proud of the continued momentum behind BRIUMVI, which we believe is establishing itself as a leading anti-CD20 therapy in adults with relapsing MS. The strong uptake we’re seeing, combined with deepening physician confidence and compelling patient experiences, underscores the strength of our launch strategy and gives us confidence in reaching our updated 2025 full year BRIUMVI U.S. net revenue guidance of $570 to $575 million. With important innovations like our subcutaneous formulation and combined day one and day fifteen IV dosing currently being studied, we believe BRIUMVI is well positioned to lead the class and redefine treatment expectations for people living with MS.”
https://www.tipranks.com/news/the-fly/tg-therapeutics-reports-q2-eps-17c-consensus-29c-thefly
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.